Phenibut

Adera

$65.00

0mg · capsule

Phenibut's pharmacology is dominated by activity at the GABA-B receptor, with secondary effects at GABA-A receptors and voltage-gated calcium channels. Understanding these three components is essential to understanding both its therapeutic effects and its dependence liability.

GABA-B agonism (primary mechanism). The GABA-B receptor is a metabotropic, G-protein-coupled receptor (Gi/Go-coupled) that — unlike the ionotropic GABA-A receptor — produces slower, longer-lasting inhibitory effects through reduction of cAMP, activation of potassium channels, and inhibition of presynaptic calcium channels. GABA-B agonism reduces neuronal excitability across limbic, cortical, and spinal circuits. Phenibut binds GABA-B receptors as a full agonist, with potency in the low micromolar range — substantially weaker than baclofen on a per-molecule basis but achievable at the oral doses humans typically take (250-1000 mg). The anxiolytic, muscle-relaxant, and mildly euphoric effects of phenibut at higher doses are largely attributable to GABA-B agonism. This mechanism is shared with baclofen (used clinically for spasticity and, off-label, for alcohol use disorder) and with GHB (used clinically for narcolepsy/cataplexy as sodium oxybate and as a drug of abuse). All three compounds produce cross-tolerance and cross-dependence, which is why transitioning between them — or combining them — is clinically unwise.

GABA-A activity (secondary). At higher doses, phenibut produces weak positive modulation of GABA-A receptors, particularly at sites relevant to sedation and anxiolysis. This component is much weaker than GABA-B agonism in phenibut's overall pharmacology, but it contributes to the sedation, impaired motor coordination, and respiratory depression seen at high doses, and it creates cross-tolerance with benzodiazepines, z-drugs (zolpidem, zopiclone), and alcohol. This is why phenibut should never be combined with alcohol, benzodiazepines, or opioids — the additive respiratory and CNS depression can be fatal, and several case reports of phenibut-related deaths involve polydrug use with these agents.

Voltage-gated α2δ calcium channel binding. Like gabapentin and pregabalin, phenibut binds to the α2δ-1 subunit of presynaptic voltage-gated calcium channels, reducing calcium influx and thereby reducing release of excitatory neurotransmitters (glutamate, norepinephrine, substance P). This mechanism contributes to phenibut's anxiolytic and, potentially, mild analgesic effects, and it distinguishes phenibut's receptor pharmacology from baclofen (which has minimal α2δ activity). The α2δ component is weaker in phenibut than in purpose-designed α2δ ligands like pregabalin, but it is not negligible and may explain some of the qualitative differences users describe between phenibut and baclofen.

Dopaminergic and monoaminergic effects. Some early Soviet literature reported that phenibut modestly increases dopamine release in limbic circuits, which may contribute to the mild euphoria and social disinhibition users report at moderate-to-high doses. This dopaminergic component is less well characterised than the GABA-B mechanism but likely contributes to phenibut's reinforcing properties and abuse potential. Unlike classical stimulants, phenibut does not inhibit dopamine reuptake or directly activate dopamine receptors — its effects on dopamine are secondary to GABA-B-mediated disinhibition of dopaminergic circuits.

Pharmacokinetics. Phenibut is well-absorbed orally with peak plasma concentrations at 2-4 hours. It crosses the blood-brain barrier readily owing to the phenyl ring. Plasma half-life is approximately 5-8 hours in humans, though central effects may persist longer because of slow brain clearance. It is not significantly metabolised by hepatic CYP enzymes in a clinically meaningful way — phenibut is primarily excreted unchanged or as minor metabolites via the kidneys. This has two practical implications: renal impairment prolongs exposure and increases overdose risk, and phenibut has fewer pharmacokinetic drug-drug interactions than most psychotropic medications. Pharmacodynamic interactions (with other CNS depressants) are the far greater concern.

Tolerance and neuroadaptation. Repeated daily dosing of phenibut produces rapid tolerance — users commonly report that within 1-2 weeks of daily use, the anxiolytic effect diminishes substantially. This mirrors the tolerance pattern seen with benzodiazepines and alcohol and reflects downregulation of GABA-B receptor density and sensitivity, plus compensatory upregulation of excitatory (glutamatergic) signalling. When phenibut is abruptly discontinued after chronic use, the hyperexcitatory state that was previously suppressed by GABA-B agonism is unmasked — this is the physiological basis of phenibut withdrawal. The severity of withdrawal scales with duration and dose: occasional single doses (say, one per week) produce no detectable withdrawal in most users, whereas daily dosing for 2-4 weeks at typical recreational doses (1-2 grams/day) can produce a withdrawal syndrome requiring medical management.

What phenibut is NOT. Phenibut is not a racetam (no structural or mechanistic relationship to piracetam, aniracetam, or noopept). It is not a benzodiazepine (does not bind the benzodiazepine site on GABA-A, though there is cross-tolerance via the broader GABAergic system). It is not a stimulant or wakefulness agent (it is sedating, not stimulating). It is not a selective anxiolytic like buspirone (which targets 5-HT1A). It is not a "natural" supplement in any meaningful sense — despite being sold alongside amino acids and vitamins, it is a synthetic pharmaceutical with a well-characterised pharmacology and a clearly demonstrated dependence profile.

Phenibut is the common Western name for β-phenyl-γ-aminobutyric acid (beta-phenyl-GABA; Russian trade names Phenibut/Фенибут, Noofen, Anvifen), a Soviet-era anxiolytic and nootropic developed in the 1960s at the Herzen State Pedagogical Institute in Leningrad under Vsevolod Vasilievich Perekalin. Structurally, it is the GABA molecule with a phenyl ring attached to the β-carbon — a modification that dramatically increases lipophilicity and allows the compound to cross the blood-brain barrier (unlike GABA itself, which does not meaningfully penetrate the CNS after oral dosing). In the Soviet Union and, later, the Russian Federation and several CIS states, phenibut is a prescription medication approved for asthenia, generalised anxiety, pre-operative anxiety, insomnia related to anxiety, post-traumatic stress reactions, vestibular disorders, motion sickness, stuttering, and several pediatric indications. It was reportedly included in the Soviet cosmonaut medical kit in the 1970s — a detail endlessly repeated in online marketing that is often used to imply safety and efficacy, though the actual context (managing acute stress in a highly selected, closely monitored population) is quite different from the way most contemporary users take it.

Outside of Russia and the CIS, phenibut has no regulatory approval. It is not a recognised medicine in the United States, the United Kingdom, the European Union, Canada, or Australia, and it is not listed on any Western pharmacopoeia. Its legal status is fragmented: Australia classifies it as a Schedule 9 prohibited substance; Hungary and several European countries treat it as a controlled substance; Lithuania, Latvia, Finland, and Italy have placed it under medicines regulation; the United Kingdom controls it under the Psychoactive Substances Act 2016. In the United States, phenibut is unscheduled at the federal level but the FDA has formally warned that it does not meet the statutory definition of a dietary supplement under DSHEA, issuing warning letters to multiple vendors in 2019 and 2020 for marketing phenibut-containing products. Despite this, it has been sold online as a nootropic powder or capsule under names like "Phenibut HCl" or "Phenibut FAA" (free amino acid form) for over a decade, often at doses and in contexts that Russian prescribers would consider grossly inappropriate.

The core pharmacology of phenibut is that it is a GABA-B receptor agonist — in the same receptor family as baclofen and the recreational drug gamma-hydroxybutyrate (GHB) — with weaker activity at GABA-A receptors and some binding to voltage-gated α2δ calcium channels similar to pregabalin and gabapentin. This combination produces anxiolysis, mild sedation, euphoria at higher doses, and — critically — the capacity to produce severe physical dependence and withdrawal after repeated use. Phenibut's withdrawal syndrome closely resembles combined benzodiazepine and alcohol withdrawal, with insomnia, severe rebound anxiety, tremor, perceptual disturbances, and in case reports, seizures and delirium. The withdrawal risk is the single most important thing any prospective user needs to understand, and it is the primary reason phenibut appears on harm-reduction lists and clinician warning pages.

The Western nootropic community's relationship with phenibut has shifted over the past decade. Early online discussion (roughly 2010-2016) treated it as a relatively benign "smart drug" or occasional anxiolytic, often with inadequate attention to tolerance and withdrawal. Over time — as case reports of severe withdrawal accumulated on PubMed (PMID 28498611, PMID 31524352, PMID 29870003, PMID 30339766, among others) and as poison control centres in Australia, Finland, and the United States began reporting regular phenibut-related calls — the community has become substantially more cautious. Responsible nootropic resources now categorise phenibut as a compound with legitimate short-term use cases (occasional social anxiety, jet-lag-related anxiety, pre-exam stress) but a narrow therapeutic window and a steep risk curve that escalates rapidly with frequency of use. Anyone considering phenibut needs to read the contraindications and protocol sections below before the description.

For a more rigorously evidence-based approach to anxiety, Western first-line treatments include SSRIs (sertraline, escitalopram), SNRIs (venlafaxine, duloxetine), and cognitive-behavioural therapy, all with substantially more strong trial data than phenibut. For acute situational anxiety in settings where a prescription is available, a single dose of propranolol or a short-acting benzodiazepine under medical supervision carries its own risks but is a better-characterised option. For a stimulant-free anxiolytic with a much lower dependence profile, see l-theanine — it lacks phenibut's potency but does not produce meaningful tolerance or withdrawal. For Russian-origin nootropics with similar geographic provenance but a very different safety profile, see selank and semax, which are peptides without the dependence liability. Phenibut is not in the same safety category as any of those compounds and should not be substituted for them without understanding the differences.

IUPAC Name

Not yet available

CAS Number

Not yet available

Molecular Formula

Not yet available

Molecular Mass

179.22 g/mol (free base); 215.68 g/mol (HCl salt)

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Get Phenibut Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it. Current lowest: $65.00

Related Compounds

Side-by-Side Comparisons

Related Articles

Adera

$65.00

Data Completeness